EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

被引：3
作者：
Le, Xiuning [1 ]
Nadler, Eric [2 ]
Costa, Daniel B. [3 ]
Heymach, John Victor [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA
来源：
TARGETED ONCOLOGY | 2023年 / 18卷 / 06期
关键词：
AFATINIB; OSIMERTINIB; NSCLC;
D O I：
10.1007/s11523-023-00994-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[media not available: see fulltext]
引用
收藏
页码：807 / 817
页数：11
相关论文
共 50 条
[31]   Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report [J].
Yang, James Chih-Hsin ;
Schuler, Martin ;
Popat, Sanjay ;
Miura, Satoru ;
Park, Keunchil ;
Passaro, Antonio ;
De Marinis, Filippo ;
Solca, Flavio ;
Maerten, Angela ;
Kim, Edward S. .
FRONTIERS IN ONCOLOGY, 2022, 12
[32]   Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations [J].
Leah Wells ;
Angel Qin .
Current Treatment Options in Oncology, 2023, 24 :1802-1814
[33]   Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations [J].
Wells, Leah ;
Qin, Angel .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) :1978-1993
[34]   Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis [J].
Jia, Caiyan ;
Xu, Qian ;
Zhao, Lu ;
Kong, Fanming ;
Jia, Yingjie .
TRANSLATIONAL ONCOLOGY, 2024, 39
[35]   Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase Inhibitors [J].
Ansen, Sascha ;
Bangard, Christopher ;
Querings, Silvia ;
Gabler, Franziska ;
Scheffler, Matthias ;
Seidel, Daniela ;
Saal, Beate ;
Zander, Thomas ;
Nogova, Lucia ;
Toepelt, Karin ;
Markert, Eva ;
Stoelben, Erich ;
Ernestus, Karen ;
Thomas, Roman K. ;
Wolf, Juergen .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) :407-409
[36]   Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence [J].
Attili, Ilaria ;
Passaro, Antonio ;
Pisapia, Pasquale ;
Malapelle, Umberto ;
de Marinis, Filippo .
CURRENT ONCOLOGY, 2022, 29 (01) :255-266
[37]   A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer [J].
Gawli, Chandrakant S. ;
Patil, Chandragouda R. ;
Patel, Harun M. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2025, 123
[38]   Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China [J].
Jianlin Xu ;
Yanwei Zhang ;
Bo Jin ;
Tianqing Chu ;
Xue Dong ;
Haitang Yang ;
Dan Wu ;
Yuqing Lou ;
Xueyan Zhang ;
Huiming Wang ;
Baohui Han .
Journal of Cancer Research and Clinical Oncology, 2016, 142 :1325-1330
[39]   Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China [J].
Xu, Jianlin ;
Zhang, Yanwei ;
Jin, Bo ;
Chu, Tianqing ;
Dong, Xue ;
Yang, Haitang ;
Wu, Dan ;
Lou, Yuqing ;
Zhang, Xueyan ;
Wang, Huiming ;
Han, Baohui .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (06) :1325-1330
[40]   Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients [J].
Chen, Kaiyan ;
Yu, Xiaoqing ;
Wang, Haiyang ;
Huang, Zhiyu ;
Xu, Yanjun ;
Gong, Lei ;
Fan, Yun .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) :1179-1187
12345